Get the Stockscreener App
30.74
6.28%
-2.06
After Hours:
31.29
0.55
+1.79%
Jyong Biotech Ltd stock is traded at $30.74, with a volume of 246.92K.
It is down -6.28% in the last 24 hours and down -48.77% over the past month.
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
See More
Previous Close:
$32.80
Open:
$32.8
24h Volume:
246.92K
Relative Volume:
0.70
Market Cap:
$2.34B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-19.51%
1M Performance:
-48.77%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$30.62
$37.85
1-Week Range:
$26.21
$40.25
52-Week Range:
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
30.74 | 2.49B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jyong Biotech Ltd Stock (MENS) Latest News
Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance
Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com India
Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - MarketScreener
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes - The Manila Times
Jyong Biotech (Nasdaq: MENS) MCS-8 Phase II Cuts Prostate Cancer 27%, High-Grade 17% - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech Ltd. (MENS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech plunges 49% after InvestingPro’s overvalued warning By Investing.com - Investing.com South Africa
Google, Alibaba among market cap stock movers on Monday - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Google and Micron among market cap stock movers on Monday By Investing.com - Investing.com UK
Google and Micron among market cap stock movers on Monday - Investing.com India
Jyong Biotech (MENS US): Taiwan-Based, US-Listed, Excluded from US & Global Indices - Smartkarma
Jyong Biotech (NASDAQ:MENS) Trading Down 8%Here's Why - MarketBeat
Dow notches record-high close while tech-heavy Nasdaq slips - Yahoo Finance
Dow notches record high close, traders bet on end to shutdown - Yahoo Finance
Health insurers slide after subsidies dropped from US shutdown deal - Yahoo Finance
Global shares jump as investors eye potential end to US shutdown - Yahoo Finance
Wall Street ends higher on solid data, strong earnings - Yahoo Finance
OpenAI signs $38 billion deal to use Amazon's cloud platform - Yahoo Finance
'Hopeful' We'll Find Long-term Solution On China: Illumina CEO - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Up 11.2%Here's What Happened - MarketBeat
FLOWSERVE CORPORATION (FLS) Stock, Price, News, Quotes, Forecast and Insights - MSN
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday - Benzinga
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Nigeria
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday - Investing.com India
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Down 15.6%Here's Why - MarketBeat
Tesla and Nvidia lead market cap stock movers this Tuesday - Investing.com
Here's How Much Traders Expect Meta Stock To Move After Earnings This Week - Yahoo Finance
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers - Investing.com
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers By Investing.com - Investing.com UK
New Montreal Biotech LifeLore Pathways Launches to Accelerate Microbial Innovation - Yahoo Finance
Jyong Biotech's (MENS) "Sell (E+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
BNB Jumps on CZ's Pardon - Yahoo Finance
PCI Biotech update - Yahoo Finance
Europe firms agree satellite merger to counter Starlink - Yahoo Finance
Workday Doubles Down on AI - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Up 5.8%What's Next? - MarketBeat
Bitcoin Mining Profitability Declined More Than 7% in September: Jefferies - Yahoo Finance
FDA Grants First CNPV Vouchers, Igniting Rally in Biotech Stocks - Yahoo Finance
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO - Yahoo Finance
Salesforce forecasts $60 billion in revenue by 2030, shares jump - Yahoo Finance
Tech Weekly: Samsung defies estimates, Wayve piques interest - Yahoo Finance
Jim Cramer on Inspire Medical: “They’ve Had One Execution Issue After Another” - Yahoo Finance
LEIFRAS Co., Ltd. Announces Pricing of Initial Public Offering - Yahoo Finance
Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400% - Benzinga
Jyong Biotech Ltd Stock (MENS) Financials Data
There is no financial data for Jyong Biotech Ltd (MENS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):